Progress on economic evaluation of pneumococcal vaccine
10.3760/cma.j.cn112150-20200723-01049
- VernacularTitle:肺炎球菌疫苗经济学评价最新进展
- Author:
Yuekun TANG
1
;
Xiang GUO
;
Xiaoying MA
;
Hongli JIANG
;
Yihan LU
;
Zhuoying HUANG
;
Jing QIU
;
Jia REN
;
Xiaodong SUN
Author Information
1. 复旦大学公共卫生学院，上海 200032
- Keywords:
Pneumococcal vaccines;
Review;
Economic evaluation
- From:
Chinese Journal of Preventive Medicine
2021;55(7):896-902
- CountryChina
- Language:Chinese
-
Abstract:
Review the literature on the economic evaluation of PCV-10, PCV-13 and PPSV-23 for providing references for decision-making and research in China. A total of 17 literatures were included, and the basic information to descriptive characteristics, methodology, modeling and the results were extracted. The 14 studies adopted Markov model, 2 studies adopted decision tree model and 1 study adopted probabilistic model. The cost including vaccine price and administration costs, direct medical expenses and indirect lost. All the 17 studies use QALY as the outcome, some studies also use LYG as the outcome. 9 of 13 studies (69.2%) involving people over the age of 50 concluded that pneumococcal vaccination was cost-effective. To provide effective references for decision-makers, China should collect the relevant epidemiological parameters, vaccine effect of pneumococcal disease in the Chinese population and carry out the economic evaluation of pneumococcal vaccination.
